Threshold Pharmaceuticals Announces New Data on the Combination of TH-302 and Avastin(R) (bevacizumab) in Recurrent Glioblastoma

Threshold Pharmaceuticals Announces New Data on the Combination of TH-302 and 
Avastin(R) (bevacizumab) in Recurrent Glioblastoma to Be
Presented at WFNO/SNO 
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/11/13 --  Threshold
Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new data
from an investigator-sponsored Phase 1/2 trial evaluating the
combination of its investigational hypoxia-targeted drug TH-302 and
Avastin(R) (bevacizumab) in patients with recurrent glioblastoma
following bevacizumab failure (Study 4003) will be presented at the
4th Quadrennial World Federation of Neuro-Oncology (WFNO) meeting
held in conjunction with the 18th annual 2013 Scientific Meeting and
Education Day of the Society for Neuro-Oncology (SNO). The 2013
WFNO/SNO meeting will take place November 21-24, San Francisco, CA.  
The abstract describing results from Study 4003 is now available at
http://neuro-oncology.oxfordjournals.org (Abstract #0281). The
related poster presentation is scheduled for Friday November 22,
2013, 7:00 PM - 9:00 PM Pacific Time at the 2013 WFNO/SNO meeting.  
About TH-302 
TH-302 is an investigational hypoxia-targeted drug that is designed
to be activated under tumor hypoxic conditions, a hallmark of many
cancers. Areas of low oxygen levels (hypoxia) in solid tumors are due
to insufficient blood supply as a result of aberrant vasculature.
Similarly, the bone marrow of patients with hematological
malignancies has also been shown, in some cases, to be severely
hypoxic. 
TH-302 is currently under evaluation in two Phase 3 trials: one in
combination with doxorubicin versus doxorubicin alone in patients
with soft tissue sarcoma, and the other in combination with
gemcitabine versus gemcitabine and placebo in patients with advanced
pancreatic cancer (MAESTRO). Both Phase 3 trials are being conducted
under Special Protocol Agreements with the U.S. Food and Drug
Administration (FDA). The FDA and the European Commission have
granted TH-302 Orphan Drug Designation for the treatment of soft
tissue sarcoma and pancreatic cancer. TH-302 is also being
investigated in hematological malignancies and in combination with
other therapies in a variety of solid tumors. 
Threshold has a global license and co-development agreement for
TH-302 with Merck KGaA, Darmstadt, Germany, which includes an option
for Threshold to co-commercialize in the U.S. 
About Threshold Pharmaceuticals  
Threshold Pharmaceuticals, Inc. is a biotechnology company focused on
the discovery and development of drugs targeting Tumor Hypoxia, the
low oxygen condition found in microenvironments of most solid tumors
as well as the bone marrows of some hematologic malignancies. This
approach offers broad potential to treat a variety of cancers. By
selectively targeting tumor cells, we are building a pipeline of
drugs that hold promise to be more effective and less toxic to
healthy tissues than conventional anticancer drugs. For additional
information, please visit our website (www.thresholdpharm.com). 
Forward-Looking Statements 
Except for statements of historical fact, the statements in this
press release are forward-looking statements, including statements
regarding the potential use of TH-302 to treat patients with
glioblastoma, other clinical trials of TH-302 and the therapeutic
uses and benefits of TH-302. These statements involve risks and
uncertainties that can cause actual results to differ materially from
those in such forward-looking statements. Potential risks and
uncertainties include, but are not limited to, Threshold's ability to
enroll or complete its anticipated clinical trials, the time and
expense required to conduct such clinical trials and analyze data,
issues arising in the regulatory or manufacturing process and the
results of such clinical trials (including product safety issues and
efficacy results). Further information regarding these and other
risks is included under the heading "Risk Factors" in Threshold's
Quarterly Report on Form 10-Q, which has been filed with the
Securities and Exchange Commission on November 4, 2013 and is
available from the SEC's website (www.sec.gov) and on our website
(www.thresholdpharm.com) under the heading "Investors." We undertake
no duty to update any forward-looking statement made in this news
release. 
Contact  
Laura Hansen, Ph.D.
Senior Director, Corporate Communications
Threshold Pharmaceuticals
Phone: 650-474-8206
E-mail: lhansen@thresholdpharm.com 
 
 
Press spacebar to pause and continue. Press esc to stop.